Where to buy Pexidartinib and how much it costs

Pexidartinib is a novel oral small molecule tyrosine kinase inhibitor (TKI) with potent and selective activity at the colony-stimulating factor 1 (CSF1) receptor. CSF1 is expressed at high levels in several types of solid tumors and promotes the differentiation of monocytes into tumor-associated macrophages (TAMs) and the survival of TAMs in the tumor microenvironment. TAMs in turn have immunosuppressive effects and promote tumor growth and metastasis.

Pesidartinib also inhibitsKIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 containing an internal tandem repeat mutation (FLT3-ITD). PesidatinibByDaiichi Developed by Sankyo (a Daiichi Sankyo company) and trade nameTURALIO, is indicated for the treatment of tenosynovial giant cell tumor (TGCT; also known as tenosynovial giant cell tumor or pigmented villonodular synovitis), which most commonly occurs in the synovium or tendon sheaths of joints in young people. It is a rare, locally aggressive tumor that overexpresses CSF1.

Pesidartinib is only available through a restricted program under REMS due to the risk of hepatotoxicity. Notable requirements of the REMS program include the following: Prescribers must become certified by the program by enrolling and completing training; patients must complete and sign an enrollment form to be included in the patient registry; pharmacies must be certified by the program and must only dispense prescriptions to patients who are entitled to receive pesidartinib. Pexidartinib is not on the market in China, and domestic patients cannot yet purchase this drug. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.